Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New Powerful Class of HIV Viral Drug
Summary
Company Overview Contact Info & Offices Press Releases CureHIV Press Release Share Blog Receive press releases from CureHIV: By Email PDF Version RSS Feeds: Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New Powerful Class of HIV Viral Drug Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us, agreed to provide samples of Global Humanceuticals, Incs NIAID#11039, a new powerful class of anti-HIV drug to clinical researchers.“Global Humanceuticals, Inc.’s NIAID #11039 is the first drug designed to prevent the development of resistance, the biggest nightmare in HIV treatment,” Stated Dr. Hershline.Interested parties can contact Dr. Roger Kenneth Hershline PhD MD, at CureHIV.us Headquarters by email: ### Hilton Head Island, SC, September 09, 2007 --( PR.com )-- At approximately 3:21 PM today, Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us, agreed to act as a conduit to provide samples of Global Humanceuticals, Inc’s., new extremely safe, potent and stable drug candidate to profit, non-profit, academic, government, non-government, U.S. and foreign institutions, organizations, and corporations, under mutual agreements, contracts or partnerships, to spur theoretical, objective, mechanistic, developmental or clinical research.There was, unfortunately, a communication error from the National Institute of Health (NIH of the United States) to Dr. Hershline, which prevented presentation of test results.The compound has a non-toxic alpha-glucose backbone, obtained from an abundant natural source.This active concentration is equivalent to diluting a 1% solution one million times and still remain active.The compound is highly safe and stable at ambient conditions.